Wave Life Sciences (WVE) Earnings Date & Reports

Key Takeaways

• Analysts forecast a Q1 2026 EPS loss of -$0.34 per share and revenue of approximately $8.45 million.
• Cash and cash equivalents stood at $602.1 million as of December 31, 2025, providing a runway into Q3 2028.
• Investors will focus on clinical updates for WVE-007 (obesity program) and WVE-006 (AATD or alpha-1 antitrypsin deficiency program), with data expected soon.
• Q4 2025 revenue of $17.2 million beat estimates, though EPS missed consensus.
• No specific 2026 financial guidance issued; potential GSK collaboration milestones anticipated.

Earnings Context and Why It Matters

Wave Life Sciences, a clinical-stage RNA medicines company, reports results amid heightened focus on its genetic disease and obesity pipeline. Q1 2026 earnings, due April 28, come after a strong year-end cash position and key partnership revenue from GSK. As a pre-revenue biotech with no approved products, investors prioritize cash burn, R&D progress, and clinical milestones over profitability. Recent pipeline advancements, including data readouts for WVE-007 and WVE-006, could signal transformative potential in obesity and AATD (alpha-1 antitrypsin deficiency). This report matters for gauging funding runway and near-term catalysts in a competitive biotech landscape.

Earnings Expectations

Consensus estimates call for Q1 2026 revenue of $8.45 million, down from Q4 2025's $17.2 million, reflecting collaboration and milestone timing. EPS is projected at -$0.34, aligning with ongoing R&D investments. Analysts watch cash usage after Q4 R&D expenses rose to $52.8 million, partly offset by $602 million in liquidity.

Key metrics include pipeline updates: six-month data from the INLIGHT trial's 240 mg cohort for WVE-007 (INHBE GalNAc-siRNA for obesity) and multidose results for WVE-006 (GalNAc-RNA editing for AATD). Historically, Wave's stock has shown volatility post-earnings; Q4 2025 saw a revenue beat but EPS miss, with shares reacting to clinical progress over financials.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your research process.

Market Reaction and Investor Sentiment

Heading into Q1 earnings, sentiment is cautiously optimistic, buoyed by the $602 million cash pile and impending clinical data. Shares traded around $7.18 recently, reflecting biotech sector pressures but supported by pipeline momentum. Risks include higher-than-expected cash burn or delays in data readouts, potentially amplifying volatility given historical post-earnings swings.

Forward Outlook and Key Factors to Monitor

Post-Q1, attention shifts to clinical milestones. Wave expects INLIGHT trial updates for WVE-007 in obesity, including Phase 2a multidose data in H1 2026, alongside add-on studies with incretins. For WVE-006, 400 mg multidose results and regulatory feedback on accelerated approval for AATD are due mid-2026.

GSK collaboration could yield milestones in 2026, bolstering revenue. Cash runway into Q3 2028 affords flexibility for pipeline expansion, including CTA for WVE-008 (PNPLA3 liver disease) and NDA for WVE-N531 (DMD exon 53).

Monitor R&D spend trends, as FY 2025 expenses hit $182.8 million amid program acceleration. Broader factors include biotech funding environment and obesity/AATD market dynamics.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations